ESTRO 2024 - Abstract Book

S2553

Clinical - Urology

ESTRO 2024

There were no differences in acute (urinary and/or intestinal) or late intestinal toxicities between the two groups (p>0.05).

No grade ≥3 acute toxicities or grade ≥2 late toxicities were reported.

Conclusion:

To our knowledge, there are no studies comparing directly the QoL and toxicity between patients with HA and balloon rectal spacers, undergoing treatment with robotic stereotactic radiotherapy.

QoL in the urinary or intestinal domains appears similar between patients with HA or balloon rectal spacers. Our study showed that patients with balloon spacers had a greater perirectal distance and experienced more grade 1 late urinary toxicities compared to the group with HA spacers.

There are different rectal spacers available, but currently no clearly defined criteria exist to aid the selection process for each patient. Therefore, studies comparing different types of spacers could be of benefit for clinical practice.

Keywords: prostate cancer, quality of life, radiosurgery

References:

1. Mariados NF, Orio PF, Schiffman Z, Van TJ, Engelman A, Nurani R, et al. Hyaluronic Acid Spacer for Hypofractionated Prostate Radiation Therapy: A Randomized Clinical Trial. JAMA Oncol [Internet]. 2023 Apr 1 [cited 2023 Oct 25];9(4):511. Available from: https://jamanetwork.com/journals/jamaoncology/fullarticle/2801296 2. Pinkawa M, Berneking V, Schlenter M, Krenkel B, Eble MJ. Quality of Life After Radiation Therapy for Prostate Cancer With a Hydrogel Spacer: 5-Year Results. International Journal of Radiation Oncology*Biology*Physics [Internet]. 2017 Oct [cited 2023 Oct 25];99(2):374 – 7. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0360301617309732

2592

Digital Poster

Early Results of Curative Intent Radiotherapy in Low Burden Metastatic Prostate Cancer

Muhsina Vellengara, Mahmoud Alfishawy, Iqbal Al Amri, Zahid AlMandhari, Jean-Philippe Pignol, Nadeem Pervez

Sultan Qaboos Comprehensive Cancer Centre, Radiation Oncology, Muscat, Oman

Purpose/Objective:

Prostate cancer is generally diagnosed at late stages in Oman. We prospectively treated low burden metastatic prostate adenocarcinoma patients with radical doses of radiotherapy and androgen deprivation therapy (ADT). We report here the early PSA response and toxicity.